MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too

When an appeals board of the U.S. Patent and Trademark Office ruled Wednesday to uphold Novartis’ patent on multiple sclerosis drug Gilenya, it was also good news for rival Celgene. The decision pushes Novartis’ exclusivity on Gilenya from 2019 to 2027.